knowledge -WSS

knowledge

author：comprehensive 2025-09-28 15:55:29 - browse：1491

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Involuntary treatment for addiction doesn't work

WSS

Washington mulls new rules to avert another Change Healthcare

Steward Health Care has deal to sell doctor network to UnitedHealth

Does aspartame cause cancer? What new WHO guidance says

Care demand spikes challenge UnitedHealth’s provider arm

Why police arrested suspected Gilgo Beach killer away from his house

The Readout: Lenmeldy, GLP

knowledge

knowledge

focus

Continuity nursing helped my family in our darkest PICU moments

Abortion pill Supreme Court ruling could impact entire drug industry

Guidelines to prevent youth baseball injuries need more muscle

Food as medicine: Medically tailored meals may get standardized

Guidelines to prevent youth baseball injuries need more muscle

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Virginia high school admissions case could be legal follow

Washington mulls new rules to avert another Change Healthcare

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Vertex Pharmaceuticals may move headquarters in Boston

explore

Eli Lilly to acquire Versanis in heated race for weight loss drugs

J&J expands global access to TB drug amid advocacy campaign

There's no autism epidemic. It's an autism diagnosis epidemic

Congress likely to miss an opportunity to fix drug shortages issue

Decaf coffee targeted by food safety group under obscure FDA rule

Washington mulls new rules to avert another Change Healthcare

focus

focus

explore

focus